Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations
July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene. It is …
Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations Read more »